by stefan | Apr 17, 2019 | Blog
ROTTERDAM, 17 April 2019 – Swanbridge Capital, an early-stage Life Sciences venture capital fund, today announced the closing of a Seed investment in Allero Therapeutics, a biopharmaceutical company focused on the discovery and development of novel immunotherapies....
by stefan | Dec 21, 2018 | Blog, Geen categorie
TILBURG, The Netherlands, 20 December 2018 – DegenRx B.V. a biopharmaceutical company developing novel therapeutic solutions to treat neurodegenerative diseases, announced today that they have secured financing for their antibody-based gene therapy program for the...
by stefan | Jul 20, 2018 | Blog
Rotterdam, July 20th, 2018 – IPaDiC, a private company that aims to develop an implantable insulin pump, announced today that it has secured funding for the first phase of development. The funding allows IPaDiC to develop and validate a prototype of the insulin pump,...
by stefan | Dec 21, 2017 | Blog
Rotterdam, December 21th, 2017 – Abegaill B.V. announces the successfully closing of a seed funding round. This funding is provided by Swanbridge Capital, a Dutch life science venture capital fund, and Leander Healthcare, a Benelux medtech innovation provider. Edwin...
by stefan | Oct 17, 2017 | Blog
Rotterdam, October 17th, 2017 – Swanbridge Capital, a Dutch Life Science Venture Capital fund, today announced its investment in FABPulous B.V., a Dutch start-up company focused on the development of a new diagnostic tool that quickly distinguishes whether patients...
by stefan | Dec 14, 2016 | Blog
Rotterdam, December 15, 2016 – Swanbridge Capital today announced the launch and closing of its first life science fund. The fund, with a size of €6.5 million, will invest in early stage life sciences ventures that require capital to fund their first Proof of...
Recent Comments